| Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A randomized controlled double‐blind phase 2 Trial S Gawrieh, M Noureddin, N Loo, R Mohseni, V Awasty, K Cusi, ... Hepatology 74 (4), 1809-1824, 2021 | 224 | 2021 |
| Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in … T Momin, K Kansagra, H Patel, S Sharma, B Sharma, J Patel, R Mittal, ... EClinicalMedicine 38, 2021 | 166 | 2021 |
| New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world … U Kaul, D Parmar, K Manjunath, M Shah, K Parmar, KP Patil, A Jaiswal Cardiovascular diabetology 18, 1-11, 2019 | 117 | 2019 |
| Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study DV Parmar, KA Kansagra, JC Patel, SN Joshi, NS Sharma, AD Shelat, ... American Journal of Nephrology 49 (6), 470-478, 2019 | 55 | 2019 |
| A phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis MS Siddiqui, MO Idowu, D Parmar, BB Borg, D Denham, NM Loo, ... Clinical Gastroenterology and Hepatology 19 (12), 2670-2672, 2021 | 51 | 2021 |
| Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double … M Krishnappa, K Patil, K Parmar, P Trivedi, N Mody, C Shah, K Faldu, ... Cardiovascular diabetology 19, 1-13, 2020 | 37 | 2020 |
| Phase I clinical study of ZYAN1, a novel prolyl-hydroxylase (PHD) inhibitor to evaluate the safety, tolerability, and pharmacokinetics following oral administration in healthy … KA Kansagra, D Parmar, RH Jani, NR Srinivas, J Lickliter, HV Patel, ... Clinical Pharmacokinetics 57, 87-102, 2018 | 33 | 2018 |
| Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis R Vuppalanchi, SH Caldwell, N Pyrsopoulos, AS DeLemos, S Rossi, ... Journal of hepatology 76 (1), 75-85, 2022 | 28 | 2022 |
| A Phase 3, Randomized, Open-label, Noninferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies … K Kansagra, D Parmar, SK Mendiratta, J Patel, S Joshi, N Sharma, ... Clinical Infectious Diseases 73 (9), e2722-e2728, 2021 | 27 | 2021 |
| A phase 2, prospective, multicenter, double-blind, randomized study of saroglitazar magnesium 1 mg, 2 mg or 4 mg versus placebo in patients with nonalcoholic fatty liver … S Gawrieh, M Noureddin, NM Loo, R Mohseni, VR Awasty, K Cusi, ... Hepatology 70 (6), 1484A-1485A, 2019 | 24 | 2019 |
| Desidustat in anemia due to non-dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-ND) D Agrawal, D Varade, H Shah, A Nazar, J Krishnan, V Shukla, ... American Journal of Nephrology 53 (5), 352-360, 2022 | 21 | 2022 |
| Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending … BE Barber, M Fernandez, HB Patel, C Barcelo, SD Woolley, H Patel, ... The Lancet Infectious Diseases 22 (6), 879-890, 2022 | 19 | 2022 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple … DV Parmar, KA Kansagra, T Momin, HB Patel, GA Jansari, J Bhavsar, ... Clinical pharmacology in drug development 12 (2), 202-211, 2023 | 16 | 2023 |
| History of insulin. SN Shah, SR Joshi, DV Parmar JAPI 97, 1-1, 1997 | 14 | 1997 |
| Saroglitazar, a dual PPAR α/γ agonist, improves atherogenic dyslipidemia in patients with non-cirrhotic nonalcoholic fatty liver disease: a pooled analysis MS Siddiqui, D Parmar, F Sheikh, SK Sarin, L Cisneros, S Gawrieh, ... Clinical Gastroenterology and Hepatology 21 (10), 2597-2605. e2, 2023 | 12 | 2023 |
| Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study A Rastogi, RL Dunbar, HP Thacker, J Bhatt, K Parmar, DV Parmar Acta Diabetologica 57, 809-818, 2020 | 12 | 2020 |
| Effect of food on the pharmacokinetics of saroglitazar magnesium, a novel dual PPARαγ agonist, in healthy adult subjects MR Patel, KA Kansagra, DP Parikh, DV Parmar, HB Patel, MM Soni, ... Clinical Drug Investigation 38, 57-65, 2018 | 11 | 2018 |
| A multicenter, open-label, single-arm study to evaluate the efficacy and safety of Saroglitazar in patients with primary biliary cholangitis R Vuppalanchi, MS González-Huezo, R Payan-Olivas, ... Clinical and Translational Gastroenterology 12 (4), e00327, 2021 | 10 | 2021 |
| Knowledge of zoonotic diseases among dairy farmers of Banaskantha district. MB Rajput, AS Sheikh, DV Parmar | 10 | 2015 |
| Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients MS Siddiqui, D Parmar, F Shaikh, M Forsgren, S Patel, AT Bui, S Boyett, ... Liver Transplantation 29 (9), 979-986, 2023 | 9 | 2023 |
